Enhertu 100 mg Trastuzumab-Deruxtecan

Description

Enhertu 100 mg Trastuzumab-Deruxtecan is used to treat adult patients with advanced her+ breast cancer or advanced her2+ gastric (stomach) or gastroesophageal junction (GEJ) cancer. Enhertu 100 mg, produced by AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Company Limited, is used in breast cancer and stomach cancer indications. The drug, approved by the European Medicine Agency (EMA), Food and Drug Administration (FDA), and Medicines and Medical Devices Agency (PMDA), is given directly intravenously.